(VIANEWS) - BioNTech SE (BNTX), Ameresco (AMRC), Huntsman Corporation (HUN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. BioNTech SE (BNTX)
1145.1% sales growth and 133.85% return on equity
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.
BioNTech SE's sales growth this year is anticipated to be 3227% and 4.1% for next year.
Year-on-year quarterly revenue growth grew by 12630.2%, now sitting on 7.77B for the twelve trailing months.
Volume
Today's last reported volume for BioNTech SE is 1692210 which is 49.15% below its average volume of 3328290.
BioNTech SE's sales growth is a negative 0% for the ongoing quarter and 1145.1% for the next. The company's growth estimates for the ongoing quarter and the next is 1188.8% and 438%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 133.85%.
Volatility
BioNTech SE's last day, last week, and last month's current intraday variation average was 6.73%, 2.60%, and 5.57%, respectively.
BioNTech SE's highest amplitude of average volatility was 8.75% (day), 5.91% (last week), and 6.50% (last month), respectively.
BioNTech SE's Stock Yearly Top and Bottom Value
BioNTech SE's stock is valued at $253.65 at 10:22 EST, way below its 52-week high of $464.00 and way higher than its 52-week low of $80.55.
BioNTech SE's Moving Average
BioNTech SE's worth is below its 50-day moving average of $269.93 and under its 200-day moving average of $268.56.Previous days news about BioNTech SE(BNTX)
- According to Bloomberg Quint on Thursday, 30 December, "The study from the University of Cape Town's Institute of Infectious Disease and Molecular Medicine looked at patients who had recovered from Covid or been vaccinated with shots from Pfizer Inc. and partner BioNTech SE or Johnson & Johnson. "
- According to Bloomberg Quint on Thursday, 30 December, "The study from the University of Cape Town's Institute of Infectious Disease and Molecular Medicine looked at patients who had recovered from Covid or been vaccinated with shots from Pfizer Inc. and partner BioNTech SE or Johnson & Johnson. "
2. Ameresco (AMRC)
88% sales growth and 12.26% return on equity
Ameresco, Inc. provides comprehensive energy services for businesses and organizations in North America and Europe.
Ameresco's sales growth this year is anticipated to be 17.2% and 44.7% for next year.
Year-on-year quarterly revenue growth declined by 3.1%, now sitting on 1.11B for the twelve trailing months.
Volume
Today's last reported volume for Ameresco is 336785 which is 8.68% above its average volume of 309883.
Ameresco's sales growth for the next quarter is 88%. The company's growth estimates for the present quarter and the next is a negative 10.6% and 64%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.26%.
Volatility
Ameresco's last day, last week, and last month's current intraday variation average was 0.90%, 1.87%, and 2.43%, respectively.
Ameresco's highest amplitude of average volatility was 3.44% (day), 4.25% (last week), and 5.31% (last month), respectively.
Ameresco's Stock Yearly Top and Bottom Value
Ameresco's stock is valued at $80.19 at 10:22 EST, way below its 52-week high of $101.86 and way above its 52-week low of $37.70.
Ameresco's Moving Average
Ameresco's value is below its 50-day moving average of $84.68 and way above its 200-day moving average of $65.25.3. Huntsman Corporation (HUN)
12.9% sales growth and 19.25% return on equity
Huntsman Corporation manufactures and sells differentiated organic chemical products worldwide.
Huntsman Corporation's sales growth this year is anticipated to be 28.3% and 2.1% for next year.
Year-on-year quarterly revenue growth grew by 62.3%, now sitting on 7.04B for the twelve trailing months.
Volume
Today's last reported volume for Huntsman Corporation is 1938470 which is 15.48% below its average volume of 2293550.
Huntsman Corporation's sales growth for the next quarter is 12.9%. The company's growth estimates for the current quarter and the next is 187.5% and 39.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.25%.
Volatility
Huntsman Corporation's last day, last week, and last month's current intraday variation average was 1.01%, 1.05%, and 1.25%, respectively.
Huntsman Corporation's highest amplitude of average volatility was 1.85% (day), 1.92% (last week), and 2.29% (last month), respectively.
Huntsman Corporation's Stock Yearly Top and Bottom Value
Huntsman Corporation's stock is valued at $32.36 at 10:22 EST, below its 52-week high of $34.47 and way higher than its 52-week low of $24.10.
Huntsman Corporation's Moving Average
Huntsman Corporation's value is under its 50-day moving average of $32.61 and way above its 200-day moving average of $28.82.4. Alexion Pharmaceuticals (ALXN)
7.4% sales growth and 4.43% return on equity
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products.
Alexion Pharmaceuticals's sales growth this year is expected to be 10.6% and 7% for next year.
Year-on-year quarterly revenue growth grew by 13.3%, now sitting on 6.26B for the twelve trailing months.
Alexion Pharmaceuticals's sales growth for the next quarter is 7.4%. The company's growth estimates for the present quarter and the next is 7.1% and 4.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.43%.
Alexion Pharmaceuticals's Stock Yearly Top and Bottom Value
Alexion Pharmaceuticals's stock is valued at $0.00 at 10:22 EST, under its 52-week low of $99.91.
Alexion Pharmaceuticals's Moving Average
Alexion Pharmaceuticals's value is below its 50-day moving average of $182.75 and below its 200-day moving average of $165.77.5. Haverty Furniture Companies (HVT)
7.4% sales growth and 32.89% return on equity
Haverty Furniture Companies, Inc. operates as a specialty retailer of residential furniture and accessories in the United States.
Haverty Furniture Companies's sales growth this year is anticipated to be 33.9% and 1.4% for next year.
Year-on-year quarterly revenue growth grew by 19.7%, now sitting on 988.2M for the twelve trailing months.
Volume
Today's last reported volume for Haverty Furniture Companies is 262165 which is 13.93% above its average volume of 230098.
Haverty Furniture Companies's sales growth is a negative 0% for the ongoing quarter and 7.4% for the next. The company's growth estimates for the current quarter and the next is 19.6% and negative -10.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 32.89%.
Volatility
Haverty Furniture Companies's last day, last week, and last month's current intraday variation average was 0.80%, 1.17%, and 2.01%, respectively.
Haverty Furniture Companies's highest amplitude of average volatility was 1.83% (day), 3.37% (last week), and 3.68% (last month), respectively.
Haverty Furniture Companies's Stock Yearly Top and Bottom Value
Haverty Furniture Companies's stock is valued at $32.17 at 10:22 EST, way below its 52-week high of $52.84 and way above its 52-week low of $27.00.
Haverty Furniture Companies's Moving Average
Haverty Furniture Companies's worth is under its 50-day moving average of $32.44 and way under its 200-day moving average of $38.00.6. Sturm, Ruger & Company (RGR)
6.4% sales growth and 38.63% return on equity
Sturm, Ruger & Company, Inc., together with its subsidiaries, designs, manufactures, and sells firearms under the Ruger name and trademark in the United States.
Sturm, Ruger & Company's sales growth this year is expected to be 32.9% and a negative 16.2% for next year.
Year-on-year quarterly revenue growth grew by 49.1%, now sitting on 629.61M for the twelve trailing months.
Volume
Today's last reported volume for Sturm, Ruger & Company is 402839 which is 189.77% above its average volume of 139019.
Sturm, Ruger & Company's sales growth for the next quarter is 6.4%. The company's growth estimates for the present quarter and the next is 56.8% and 9.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 38.63%.
Volatility
Sturm, Ruger & Company's last day, last week, and last month's current intraday variation average was 0.66%, 0.98%, and 1.52%, respectively.
Sturm, Ruger & Company's highest amplitude of average volatility was 2.57% (day), 2.42% (last week), and 3.14% (last month), respectively.
Sturm, Ruger & Company's Stock Yearly Top and Bottom Value
Sturm, Ruger & Company's stock is valued at $66.71 at 10:22 EST, way under its 52-week high of $92.49 and higher than its 52-week low of $62.16.
Sturm, Ruger & Company's Moving Average
Sturm, Ruger & Company's value is below its 50-day moving average of $73.61 and way below its 200-day moving average of $74.91.7. Duke Realty Corporation (DRE)
5.8% sales growth and 7.06% return on equity
Duke Realty Corporation owns and operates approximately 156 million rentable square feet of industrial assets in 20 major logistics markets.
Duke Realty Corporation's sales growth this year is anticipated to be 12.6% and 7% for next year.
Year-on-year quarterly revenue growth grew by 27.9%, now sitting on 1.07B for the twelve trailing months.
Volume
Today's last reported volume for Duke Realty Corporation is 220201 which is 85.43% below its average volume of 1512000.
Duke Realty Corporation's sales growth for the next quarter is 5.8%. The company's growth estimates for the current quarter and the next is 15.8% and negative -53.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.06%.
Volatility
Duke Realty Corporation's last day, last week, and last month's current intraday variation average was 0.02%, 0.50%, and 1.22%, respectively.
Duke Realty Corporation's highest amplitude of average volatility was 0.90% (day), 1.25% (last week), and 1.90% (last month), respectively.
Duke Realty Corporation's Stock Yearly Top and Bottom Value
Duke Realty Corporation's stock is valued at $62.50 at 10:22 EST, above its 52-week high of $57.66.
Duke Realty Corporation's Moving Average
Duke Realty Corporation's worth is way above its 50-day moving average of $52.92 and way higher than its 200-day moving average of $49.97.8. Mondelez International (MDLZ)
5.4% sales growth and 16.11% return on equity
Mondelez International, Inc., through its subsidiaries, manufactures, markets, and sells snack food and beverage products worldwide.
Mondelez International's sales growth this year is anticipated to be 7.6% and 4% for next year.
Year-on-year quarterly revenue growth grew by 12.4%, now sitting on 27.84B for the twelve trailing months.
Volume
Today's last reported volume for Mondelez International is 1349610 which is 79.31% below its average volume of 6524590.
Mondelez International's sales growth for the next quarter is 5.4%. The company's growth estimates for the ongoing quarter and the next is 12.7% and 13.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.11%.
Volatility
Mondelez International's last day, last week, and last month's current intraday variation average was 0.94%, 0.75%, and 1.24%, respectively.
Mondelez International's highest amplitude of average volatility was 0.99% (day), 0.96% (last week), and 1.53% (last month), respectively.
Mondelez International's Stock Yearly Top and Bottom Value
Mondelez International's stock is valued at $64.92 at 10:22 EST, below its 52-week high of $65.60 and way above its 52-week low of $52.91.